Ocuclear, Rhofade, Upneeq, Visine L.r (oxymetazoline) is a small molecule pharmaceutical. Oxymetazoline was first approved as Ocuclear on 1986-05-30. It is used to treat common cold, conjunctivitis, rhinitis, and sinusitis in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor and alpha-2A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1B, alpha-2C adrenergic receptor, and 5-hydroxytryptamine receptor 1D. Afrin original's patents are valid until 2039-12-16 (FDA).
|Trade Name||Ocuclear, Rhofade, Upneeq, Visine L.r|
|Indication||common cold, conjunctivitis, rhinitis, sinusitis|
|Drug Class||Antihistamines/local vasoconstrictors (antazoline type)|